GlaxoSmithKline (GSK) has decided to stop the enrolment of patients in Phase II INDUCE-3 trial of feladilimab for PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma (PD-L1 HNSCC) treatment.
Feladilimab is an investigational inducible T cell co-stimulatory (ICOS) agonist.
The latest move follows a recommendation from the Independent Data Monitoring Committee and will also include discontinuation of the treatment with feladilimab.
The INDUCE-3 study is evaluating feladilimab plus pembrolizumab as compared with placebo plus pembrolizumab in PD-L1 HNSCC patients.
GSK will also stop the INDUCE-4 phase II trial analysing feladilimab versus placebo plus pembrolizumab and chemotherapy.
The company will analyse the totality of the data for understanding the impact on feladilimab’s overall clinical development programme.
The INDUCE-3 and INDUCE-4 trials are carried out as part of an agreement between GSK and Merck.
In a separate development, REGENXBIO has dosed the first patient in Cohort 3 of the ongoing Phase I/II trial of RGX-121 for treating Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome, in patients aged up to five years old.
An investigational one-time gene therapy, RGX-121 can potentially deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector.
In the open-label, dose-escalation trial being carried out at four clinical centres in the US and Brazil, three dose levels of RGX-121 administered directly to the cerebrospinal fluid (CSF) will be analysed.
Safety and tolerability of RGX-121 will form the study’s primary endpoint, while additional endpoints include the effect of RGX-121 on biomarkers of I2S enzyme activity in the CSF, serum and urine; neurocognitive development; and other outcome measures.
REGENXBIO chief medical officer Steve Pakola said: “We are pleased with our continued progress in the Phase I/II trial of RGX-121 as we increase the dose level to further our understanding of the potential treatment effects, including potential systemic benefit for patients.”